NDMAC Urges OTC Exclusivity In Canada Similar To U.S. Model
This article was originally published in The Tan Sheet
Executive Summary
Canadian regulators should allow three-year exclusivity for innovations in both existing and new nonprescription drug products, the country's self-care industry trade group says
You may also be interested in...
Canadian Rx-to-OTC Approval Process Could Be Smoother, GSK Exec Says
Canada's Rx-to-OTC switch process should be streamlined and made more industry-friendly, according to GlaxoSmithKline regulatory executive Jennifer Denomme
Canadian Rx-to-OTC Approval Process Could Be Smoother, GSK Exec Says
Canada's Rx-to-OTC switch process should be streamlined and made more industry-friendly, according to GlaxoSmithKline regulatory executive Jennifer Denomme
Canadian Rx-to-OTC Approval Process Could Be Smoother, GSK Exec Says
Canada's Rx-to-OTC switch process should be streamlined and made more industry-friendly, according to GlaxoSmithKline regulatory executive Jennifer Denomme